Hematologic Oncology

A new study has found an association between body mass index and the risk for multiple myeloma among African Americans in the United States.

The early 21st century has brought with it significant improvements in survival from most common hematologic malignancies for patients aged 65 years or older, but these increases still lag behind those of 50- to 59-year-olds.

Some patients with mantle cell lymphoma may safely defer treatment for their disease, and, in fact, deferral of therapy was an independent predictor of overall survival.

Independent of already known roles in impaired DNA repair, mutations in the Fanconi anemia pathway also disrupt cells’ antiviral immunity and removal of damaged mitochondria, resulting in an accumulation of mitochondrial reactive oxygen species.

Chronic myeloid leukemia patients had a significantly increased prevalence of prior malignancies and autoimmune disorders compared with the general population.

Researchers in Seattle are reporting success with an experimental therapy that modifies T cells to express a CD19-specific chimeric antigen receptor (CAR) to treat B-cell malignancies.

The addition of pegylated interferon-ɑ2b to dasatinib yielded promising results in a small trial of newly diagnosed chronic myeloid leukemia patients.

Genentech and Astex Pharmaceuticals will collaborate in a clinical trial of a combination hypomethylating and immune checkpoint blockade therapy for patients with acute myeloid leukemia.

Adding ixazomib to the combination of lenalidomide/dexamethasone resulted in a more than 35% improvement in the risk for disease progression or death in patients with relapsed or refractory multiple myeloma.

Patients with primary plasma cell leukemia experienced high rates of response and improved progression-free survival when treated with bortezomib, dexamethasone plus doxorubicin or cyclophosphamide followed by transplantation.

A 37-year old man presents with a bluish lesion in the right arm. After further assessment, a biopsy is performed. What is your diagnosis?

The efficacy of ponatinib in patients with newly diagnosed CML compared with imatinib remains to be established, as a randomized phase III trial was terminated early due to concerns regarding arterial occlusive events with ponatinib.

Risk-stratification based on a biomarker and associated prophylaxis could help reduce the incidence of graft-vs-host disease in patients undergoing haploidentical transplantation.

We review here the state of the art of diagnosis and treatment of AML and provide insights into the emerging novel biomarkers and therapeutic agents that are anticipated to be useful for the implementation of personalized medicine in AML.

Recent advances in mantle cell lymphoma include: (1) identification of new pathways to target, (2) novel therapeutics to treat patients with relapsed/refractory disease, and (3) monitoring of minimal residual disease and adoption of a maintenance therapy approach to prevent relapses post induction or post stem cell transplantation.

A rapid reduction in BCR-ABL transcript levels and the halving time of those levels are predictive of better outcomes in patients with chronic myeloid leukemia.

Overall, the future of patients with MCL is promising, since therapeutic options have widened. The implementation of universal aggressive treatment is challenged by novel regimens, targeted agents, the use of MRD to guide treatment decisions, and new trials that will directly compare transplant vs non-transplant approaches.

We are ready to move beyond a “one-size-fits-all” approach in AML and join our colleagues treating other malignancies, such as lung cancer, in moving towards a personalized medicine approach.

On April 11, 2016, The US Food and Drug Administration approved a new agent for patients with chronic lymphocytic leukemia.

Two more cancer centers have joined Intel's Collaborative Cancer Cloud data sharing and research platform, the chip maker and the Oregon Health & Science University (OHSU) have announced.

A first-in-man phase I study of CUDC-907, which targets both histone deacetylase and PI3K enzymes, has shown promise in patients with relapsed or refractory multiple myeloma or lymphoma.

The long-term use of romidepsin in a dose-sparing regimen to treat cutaneous T-cell lymphoma may be a useful strategy to try to prolong disease response.

A scoring system including several patient characteristics was found to have significant prognostic value for patients with myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation.

Patients with acute myeloid leukemia who have undergone autologous stem cell transplantation and survived without disease recurrence for at least 2 years are still at risk for late recurrences.

The FDA has approved defibrotide sodium (Defitelio) for the treatment of hepatic veno-occlusive disease following hematopoietic stem cell transplantation in both adults and children.

Patients with CML who are treated with dasatinib commonly experience lymphocytosis, and the condition is associated with higher response rates and increased survival in patients who are refractory or intolerant of imatinib.

The FDA has approved two indications of a new formulation of melphalan hydrochloride called Evomela for the treatment of multiple myeloma.

The injectable drug APO866, designed to induce apoptosis, did not have efficacy against cutaneous T-cell lymphoma, according to the results of small study.

Elevated levels of TGF-α and IL-6 in newly diagnosed chronic-phase chronic myeloid leukemia patients were predictive of failure to achieve molecular response.

Early relapse after stem cell transplant was linked with worse overall survival in multiple myeloma patients who received a novel agent prior to transplant.